Reply to ‘Challenging PD-L1 Expressing Cytotoxic T Cells as a Predictor for Response to Immunotherapy in Melanoma’

Nature Communications - United Kingdom
doi 10.1038/s41467-018-05048-0
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Nuclear IRF-1 Expression as a Mechanism to Assess “Capability” to Express PD-L1 and Response to PD-1 Therapy in Metastatic Melanoma

Journal for ImmunoTherapy of Cancer
OncologyMolecular MedicinePharmacologyCancer ResearchAllergyImmunology
2017English

Sex as a Predictor of Response to Cancer Immunotherapy

The Lancet Oncology
Oncology
2018English

Sex as a Predictor of Response to Cancer Immunotherapy

The Lancet Oncology
Oncology
2018English

Response to Nivolumab in Metastatic Collecting Duct Carcinoma Expressing PD‑L1: A Case Report

Molecular and Clinical Oncology
Cancer ResearchOncology
2017English

Imaging of Activated T Cells as an Early Predictor of Immune Response to Anti-Pd-1 Therapy

Cancer Research
Cancer ResearchOncology
2019English

BRAF Targeting Sensitizes Resistant Melanoma to Cytotoxic T Cells

Clinical Cancer Research
Cancer ResearchOncology
2019English

Circulating Tumour DNA for Monitoring Treatment Response to Anti-Pd-1 Immunotherapy in Melanoma Patients

Acta Dermato-Venereologica
DermatologyMedicine
2017English

Defining T Cell States Associated With Response to Checkpoint Immunotherapy in Melanoma

Cell
BiochemistryGeneticsMolecular Biology
2019English

Cytotoxic T Cells in PD-L1-Positive Malignant Pleural Mesotheliomas Are Counterbalanced by Distinct Immunosuppressive Factors

Cancer immunology research
Cancer ResearchImmunology
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy